Result of WRAP Retail Offer
Verici Dx Plc has successfully raised approximately £0.19 million in gross proceeds through its WRAP Retail Offer at an issue price of 0.35 pence per share, in addition to the previously announced Placing. This brings the total gross proceeds from both the Placing and the WRAP Retail Offer to approximately £2.6 million, with a total of 53,345,832 WRAP Retail Offer Shares being issued. The issuance of these shares is contingent upon shareholder approval at a General Meeting scheduled for June 22, 2026, and subsequent admission to trading on AIM.
Select text to share a quote on X · sign in to keep highlights & notes in your VRCI notes
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms, further to the announcements made on 8 June 2026, the result of its WRAP Retail Offer at the Issue Price of 0.35 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately £0.19 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing. Accordingly, the Company will issue a total of 53,345,832 WRAP Retail Offer Shares.
In total, the Placing and the WRAP Retail Offer has raised gross proceeds of approximately £2.6 million for the Company, via the Placing of 700,000,000 Placing Shares and the 53,345,832 WRAP Retail Offer Shares.
For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. The issue of the WRAP Retail Offer Shares is conditional upon:
- the passing of certain resolutions to be put to shareholders of Verici Dx plc at a General Meeting, which is expected to be held at Shoosmiths LLP's London office at 1 Bow Churchyard, London EC4M 9DQ at 11.30 a.m. on 22 June 2026; and
- the new Ordinary Shares being admitted to trading on AIM.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7am on 8 June 2026.
| Verici Dx plc Sara Barrington, CEO | www.vericidx.com |
| Julian Baines, Chairman | |
| Singer Capital Markets (Nominated Adviser, Joint Broker & Joint Bookrunner) | Tel: +44 (0)20 7496 3000 |
| Phil Davies / Jalini Kalaravy / Anastassiya Eley | |
| Oberon Capital (Joint Broker & Joint Bookrunner) | Tel: +44 (0)20 3179 0500 |
| Mike Seabrook / Adam Pollock / Heena Karani | |
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
| Alice Woodings / Rachel Broad | Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.